XML 40 R24.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Accounting for Stock Based Compensation | 12 Months Ended
--- | ---
Dec. 31, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] |
Accounting for Stock Based Compensation | Note 17 — Accounting for Stock Based Compensation On May 16, 2013, the Compensation Committee of the Company’s Board of Directors (the “Board”) approved the Gentherm Incorporated 2013 Equity Incentive Plan (the “2013 Plan”), covering 3,500,000 shares of our Common Stock. The 2013 Plan was amended on May 19, 2017 to increase the number of available shares by 2,000,000 and further amended on May 21, 2020 to increase the number of available shares by 2,450,000. The 2013 Plan permits the granting of various awards including stock options (including both nonqualified options and incentive options), stock appreciation rights (“SARs”), restricted stock and restricted stock units (“RSUs”), performance-based restricted stock units (“PSUs”) shares and certain other awards to employees, outside directors and consultants and advisors of the Company. As of December 31, 2021, the Company had an aggregate of 2,739,534 shares of Common Stock available to issue under the 2013 Plan. All equity plans are administered by the Compensation Committee of the Board. During the three-year period ended December 31, 2021, the Company has outstanding stock options, SARs, restricted stock awards and restricted stock units to employees, directors and consultants. These awards become available to the recipient upon the satisfaction of a vesting condition, either based on a period of service or based on the performance of a specific achievement. For equity-based awards with a service condition, the requisite service period typically ranges between three to four years for employees and consultants and one year for directors. As of December 31, 2021, there were 319,336 PSUs outstanding. These awards cliff vest after three-years based on the Company’s achievement of either a target return on invested capital ratio (“ROIC”), as defined in the award agreement, for a specified fiscal year a target three year cumulative Adjusted EBITDA (“Adjusted EBITDA”), as defined in the award agreement, or the Company’s relative total shareholder return (“TSR”), as defined in the award agreement, during a specific three-year measurement period. In each case, awards will be earned at 50% of the target number of shares for achieving a minimum threshold or up to 200% of the target number of shares for exceeding the target, with a linear adjustment between threshold and target or between target and stretch performance goals. All other outstanding, unvested equity-based awards were service based. Equity-based award vesting may be accelerated at the discretion of the Board under conditions specified in the 2013 plan. Under FASB ASC Topic 718, the provisions of the PSUs that vest upon the achievement of relative TSR are considered a market condition, and therefore the effect of that market condition is reflected in the grant date fair value for this portion award. A third party was engaged to complete a Monte Carlo simulation to account for the market condition. That simulation takes into account the beginning stock price of our common stock, the expected volatilities for the relative TSR comparator group, the expected volatilities for the Company’s stock price, correlation coefficients, the expected risk-free rate of return and the expected dividend yield of the Company and the comparator group. The single grant-date fair value computed by this valuation method is recognized by the Company in accounting for the awards regardless of the actual future outcome of the relative TSR feature. The grant date fair value of the other PSUs and RSUs are calculated as the closing price of our common stock as quoted on Nasdaq on the grant date multiplied by the number of shares subject to the award. Each of ROIC and Adjusted EBITDA is considered a performance condition and the grant-date fair value for ROIC PSUs and Adjusted EBITDA PSUs corresponds with management's expectation of the probable outcome of the performance condition as of the grant date. The total recognized and unrecognized stock-based compensation expense is as follows:
Stock-Based Compensation Expense |  | 2021 |  |  | 2020 |  |  | 2019 |  |  | Unrecognized Stock-Based Compensation Expense at December 31, 2021 |
Options |  | $ | 482 |  |  | $ | 836 |  |  | $ | 885 |  |  | $ | - |
Restricted Shares |  |  | 1,198 |  |  |  | 1,495 |  |  |  | 1,600 |  |  |  | 309 |
Restricted Stock Units |  |  | 4,594 |  |  |  | 3,137 |  |  |  | 1,751 |  |  |  | 7,423 |
Performance Based Units |  |  | 5,535 |  |  |  | 3,361 |  |  |  | 2,017 |  |  |  | 8,572 |
Stock Appreciation Rights |  |  | 2,721 |  |  |  | 5,494 |  |  |  | 2,336 |  |  |  | - |
Total Stock-Based Compensation |  | $ | 14,530 |  |  | $ | 14,323 |  |  | $ | 8,589 |  |  | $ | 16,304 |
The related deferred tax benefit for the years ended December 31, 2021, 2020 and 2019 was $2,725, $3,002, and $1,573, respectively. If Gentherm were to realize expired share-based payment arrangements, they would be reported as a forfeit in the activity roll forward tables below. Stock Options The following table summarizes stock option activity during the years ended December 31, 2021, 2020 and 2019:
Options |  | Shares |  |  | Weighted-Average Exercise Price |  |  | Weighted-Average Remaining Contractual Term |  |  | Aggregate Intrinsic Value |
Outstanding at December 31, 2018 |  |  | 1,653,000 |  |  | $ | 38.53 |  |  |  | 4.28 |  |  | $ | 3,610 |
Granted |  |  | — |  |  |  | — |  |  |  |  |  |  |  |  |
Exercised |  |  | (428,250 | ) |  |  | 38.66 |  |  |  |  |  |  |  |  |
Forfeited |  |  | (355,750 | ) |  |  | 39.99 |  |  |  |  |  |  |  |  |
Outstanding at December 31, 2019 |  |  | 869,000 |  |  | $ | 37.87 |  |  |  | 3.51 |  |  | $ | 5,172 |
Granted |  |  | — |  |  |  | — |  |  |  |  |  |  |  |  |
Exercised |  |  | (434,250 | ) |  |  | 38.12 |  |  |  |  |  |  |  |  |
Forfeited |  |  | (6,750 | ) |  |  | 38.05 |  |  |  |  |  |  |  |  |
Outstanding at December 31, 2020 |  |  | 428,000 |  |  | $ | 37.61 |  |  |  | 3.20 |  |  | $ | 11,815 |
Granted |  |  | — |  |  |  | — |  |  |  |  |  |  |  |  |
Exercised |  |  | (215,250 | ) |  |  | 38.46 |  |  |  |  |  |  |  |  |
Forfeited |  |  | (6,000 | ) |  |  | 38.05 |  |  |  |  |  |  |  |  |
Outstanding at December 31, 2021 |  |  | 206,750 |  |  | $ | 36.72 |  |  |  | 2.60 |  |  | $ | 10,375 |
Exercisable at December 31, 2021 |  |  | 206,750 |  |  | $ | 36.72 |  |  |  | 2.60 |  |  | $ | 10,375 |
There have been no stock options granted since the year ended December 31, 2017 and all options are currently vested. The total intrinsic value of options exercised during the years ended December 31, 2021, 2020 and 2019 was $8,269, $5,317 and $1,681, respectively. Restricted Stock The following table summarizes restricted stock activity during the years ended December 31, 2021, 2020 and 2019:
Unvested Restricted Shares |  | Shares |  |  | Weighted-Average Grant Date Fair Value |
Outstanding at December 31, 2018 |  |  | 136,566 |  |  | $ | 37.16 |
Granted |  |  | 19,920 |  |  |  | 40.16 |
Vested |  |  | (91,566 | ) |  |  | 37.09 |
Forfeited |  |  | (30,000 | ) |  |  | 38.05 |
Outstanding at December 31, 2019 |  |  | 34,920 |  |  | $ | 38.31 |
Granted |  |  | 32,406 |  |  |  | 39.96 |
Vested |  |  | (32,420 | ) |  |  | 38.33 |
Forfeited |  |  | — |  |  |  | — |
Outstanding at December 31, 2020 |  |  | 34,906 |  |  | $ | 39.82 |
Granted |  |  | 13,742 |  |  |  | 70.18 |
Vested |  |  | (37,272 | ) |  |  | 41.70 |
Forfeited |  |  | — |  |  |  | — |
Outstanding at December 31, 2021 |  |  | 11,376 |  |  | $ | 70.33 |
The compensation cost associated with restricted shares is estimated on the date of grant using quoted market prices (Level 1 input). The total fair value of restricted shares vested in 2021, 2020 and 2019 was $1,554, $1,499 and $3,697, respectively. RSUs The following table summarizes restricted stock unit activity during the years ended December 31, 2021, 2020 and 2019:
Unvested Restricted Stock Units |  | Time Vesting Shares |  |  | Weighted-Average Grant Date Fair Value |
Outstanding at December 31, 2018 |  |  | 86,392 |  |  | $ | 42.53 |
Granted |  |  | 107,391 |  |  |  | 40.99 |
Vested |  |  | (23,956 | ) |  |  | 42.62 |
Forfeited |  |  | (28,086 | ) |  |  | 39.88 |
Outstanding at December 31, 2019 |  |  | 141,741 |  |  | $ | 42.16 |
Granted |  |  | 132,864 |  |  |  | 34.41 |
Vested |  |  | (50,953 | ) |  |  | 42.13 |
Forfeited |  |  | (14,747 | ) |  |  | 39.16 |
Outstanding at December 31, 2020 |  |  | 208,905 |  |  | $ | 37.26 |
Granted |  |  | 93,539 |  |  |  | 79.79 |
Vested |  |  | (88,296 | ) |  |  | 38.49 |
Forfeited |  |  | (20,522 | ) |  |  | 48.76 |
Outstanding at December 31, 2021 |  |  | 193,626 |  |  | $ | 56.02 |
The total intrinsic value of restricted stock units vested during the years ended December 31, 2021, 2020 and 2019 was $3,398, $2,214 and $1,000, respectively. PSUs The following table summarizes performance stock unit activity during the years ended December 31, 2021, 2020 and 2019:
Unvested Performance Stock Units |  | Relative TSR Target Shares |  |  | Weighted-Average Grant Date Fair Value |  |  | ROIC Target Shares |  |  | Weighted-Average Grant Date Fair Value |  |  | Adjusted EBITDA Target Shares |  |  | Weighted-Average Grant Date Fair Value |  |  | Total |
Outstanding at December 31, 2018 |  |  | 64,785 |  |  | $ | 62.45 |  |  |  | 64,792 |  |  | $ | 42.53 |  |  |  | — |  |  | $ | — |  |  |  | 129,577 |
Granted |  |  | 56,380 |  |  |  | 57.39 |  |  |  | 56,375 |  |  |  | 41.51 |  |  |  | — |  |  |  | — |  |  |  | 112,755 |
Vested |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Forfeited |  |  | (26,124 | ) |  |  | 53.98 |  |  |  | (26,128 | ) |  |  | 39.41 |  |  |  | — |  |  |  | — |  |  |  | (52,252 | )
Outstanding at December 31, 2019 |  |  | 95,041 |  |  | $ | 61.77 |  |  |  | 95,039 |  |  | $ | 42.78 |  |  |  | — |  |  | $ | — |  |  |  | 190,080 |
Granted |  |  | 77,967 |  |  |  | 49.25 |  |  |  | 77,967 |  |  |  | 33.72 |  |  |  | — |  |  |  | — |  |  |  | 155,934 |
Vested |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Forfeited |  |  | (15,090 | ) |  |  | 56.84 |  |  |  | (15,090 | ) |  |  | 39.96 |  |  |  | — |  |  |  | — |  |  |  | (30,180 | )
Outstanding at December 31, 2020 |  |  | 157,918 |  |  | $ | 56.06 |  |  |  | 157,916 |  |  | $ | 38.58 |  |  |  | — |  |  | $ | — |  |  |  | 315,834 |
Granted |  |  | 20,626 |  |  |  | 118.08 |  |  |  | 40,580 |  |  |  | 78.98 |  |  |  | 39,930 |  |  |  | 79.49 |  |  |  | 101,136 |
Performance Adjustment |  |  | 30,828 |  |  |  | 69.18 |  |  |  | (30,830 | ) |  |  | 44.92 |  |  |  | — |  |  |  | — |  |  |  | (2 | )
Vested |  |  | (61,656 | ) |  |  | 69.18 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (61,656 | )
Forfeited |  |  | (16,148 | ) |  |  | 61.10 |  |  |  | (17,374 | ) |  |  | 44.32 |  |  |  | (2,454 | ) |  |  | 79.49 |  |  |  | (35,976 | )
Outstanding at December 31, 2021 |  |  | 131,568 |  |  | $ | 62.09 |  |  |  | 150,292 |  |  | $ | 47.52 |  |  |  | 37,476 |  |  | $ | 79.49 |  |  |  | 319,336 |
The total intrinsic value of performance stock units vested during the years ended December 31, 2021, 2020 and 2019 was $4,265, $0 and $0, respectively. SARs The following table summarizes SARs activity during the years ended December 31, 2021, 2020 and 2019:
Stock Appreciation Rights |  | Shares |  |  | Weighted-Average Exercise Price |  |  | Weighted-Average Remaining Contractual Term |  |  | Aggregate Intrinsic Value |
Outstanding at December 31, 2018 |  |  | 988,100 |  |  | $ | 40.61 |  |  |  | 3.57 |  |  | $ | 2,064 |
Granted |  |  | — |  |  |  | — |  |  |  |  |  |  |  |  |
Exercised |  |  | (179,500 | ) |  |  | 32.84 |  |  |  |  |  |  |  |  |
Forfeited |  |  | (254,350 | ) |  |  | 42.63 |  |  |  |  |  |  |  |  |
Outstanding at December 31, 2019 |  |  | 554,250 |  |  | $ | 39.41 |  |  |  | 2.84 |  |  | $ | 2,981 |
Granted |  |  | — |  |  |  | — |  |  |  |  |  |  |  |  |
Exercised |  |  | (342,150 | ) |  |  | 38.22 |  |  |  |  |  |  |  |  |
Forfeited |  |  | (40,500 | ) |  |  | 44.39 |  |  |  |  |  |  |  |  |
Outstanding at December 31, 2020 |  |  | 171,600 |  |  | $ | 40.60 |  |  |  | 2.44 |  |  | $ | 4,224 |
Granted |  |  | — |  |  |  | — |  |  |  |  |  |  |  |  |
Exercised |  |  | (116,000 | ) |  |  | 40.34 |  |  |  |  |  |  |  |  |
Forfeited |  |  | — |  |  |  | — |  |  |  |  |  |  |  |  |
Outstanding at December 31, 2021 |  |  | 55,600 |  |  | $ | 41.15 |  |  |  | 1.28 |  |  | $ | 2,544 |
Exercisable at December 31, 2021 |  |  | 55,600 |  |  | $ | 41.15 |  |  |  | 1.28 |  |  | $ | 2,544 |
There have been no SARs granted since the year ended December 31, 2017 and all SARs are currently vested. The total intrinsic value of SARs exercised during the years ended December 31, 2021, 2020 and 2019 was $4,301, $4,164 and $1,588, respectively.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration